Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.77 |
| ▸ | ESR1 | P03372 | 1/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.77 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.77 |
| ▸ | AR | P10275 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524821 | 0.92 | NR1H4 (0.77) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL28819549 | 0.91 | NR1H4 (0.76) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4531506 | 0.90 | NR1H4 (0.82) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL5732802 | 0.90 | NR1H4 (0.63) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4309430 | 0.89 | NR1H4 (0.76) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4524306 | 0.89 | NR1H4 (0.75) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4524962 | 0.88 | NR1H4 (0.61) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL16917651 | 0.88 | NR1H4 (0.74) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL24258009 | 0.87 | NR1H4 (0.75) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL273529 | 0.87 | NR1H4 (1.00) | NR1H4ESR1NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532153-B1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2012-02-29 | — | — | EP | claimed |
| US-20160015819-A1 | FATTY ACID CONJUGATES OF STATIN AND FXR AGONISTS: COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160015819-A1 | FATTY ACID CONJUGATES OF STATIN AND FXR AGONISTS: COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9084826-B2 | Fatty acid conjugates of statin and FXR agonists; compositions and method of uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9084826-B2 | Fatty acid conjugates of statin and FXR agonists; compositions and method of uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015819-A1 | FATTY ACID CONJUGATES OF STATIN AND FXR AGONISTS: COMPOSITIONS AND METHODS OF USE | SLC10A1, NR1H4, FXR1 | NR1H4 2/4885ESR1 991/4885NR3C1 299/4885 |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | NR1H4 1/4885ESR1 292/4885NR3C1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.